Irisolidone Ameliorates Cyclophosphamide-Induced POI via Inhibiting Inflammatory Response
The present study demonstrates that Irisolidone can effectively alleviate CTX-induced POI by inhibiting abnormal inflammation. These findings suggest that Irisolidone holds promise as a novel therapeutic candidate for POI, thereby providing a potential new treatment strategy for clinical management of this condition.
Authors
- Shouye Ma (ORCID: https://orcid.org/0000-0003-1894-5064)
- Mingjin Li (ORCID: https://orcid.org/0009-0002-9438-1387)
- Jiyu Chen (ORCID: https://orcid.org/0000-0002-5084-539X)
- Yaping Pei (ORCID: https://orcid.org/0000-0002-5635-556X)
- Zhenhong Wei (ORCID: https://orcid.org/0000-0001-8494-7610)
- Xiaohong Chen (ORCID: https://orcid.org/0000-0001-7810-8271)
- Huifang Wu (ORCID: https://orcid.org/0009-0000-4373-0888)
- Xue Han (ORCID: https://orcid.org/0009-0001-5812-9363)
Institutions
- Guiyang College of Traditional Chinese Medicine (CN)
- Guiyang Medical University (CN)
- Affiliated Hospital of Guizhou Medical University (CN)
- Gansu Provincial Hospital (CN)
Publication Details
- Journal
- Frontiers in Bioscience-Landmark
- Published
- 2025-11-26
- DOI
- https://doi.org/10.31083/fbl45744
- Primary Topic
- Nausea and vomiting management
- Type
- article
- Field-Weighted Citation Impact
- 0.00